Business

Announcement on Voluntary Disclosure of Initiation of Phase I Clinical Trial for Trivalent and Tetravalent Influenza Vaccine (Split Virus, MDCK Cells) and Completion of First Subject Enrollment

Announcement on Voluntary Disclosure of Initiation of Phase I Clinical Trial for Trivalent and Tetravalent Influenza Vaccine (Split Virus, MDCK Cells) and Completion of First Subject Enrollment

articleChengdu Olymvax Biopharmaceuticals Inc. Class AFebruary 21, 20255/news/announcement-on-voluntary-disclosure-of-initiation-of-phase-i-clinical-trial-for-trivalent-and-tetravalent-influenza-vaccine-split-virus-mdck-cells-and-completion-of-first-subject-enrollment
Announcement on Voluntary Disclosure of Initiation of Phase I Clinical Trial for Trivalent and Tetravalent Influenza Vaccine (Split Virus, MDCK Cells) and Completion of First Subject Enrollment

About this update from Chengdu Olymvax Biopharmaceuticals Inc. Class A

Announcement on Voluntary Disclosure of Initiation of Phase I Clinical Trial for Trivalent and Tetravalent Influenza Vaccine (Split Virus, MDCK Cells) and Completion of First Subject EnrollmentThe abstract is for reference only. Please refer to the full text of the announcement on the very day.Link of Full Text for Reference: View Attachment

View stock analysis, news, and events for Chengdu Olymvax Biopharmaceuticals Inc. Class A